MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Heart Failure

Dr. Mikhail Kosiborod, cardiologist and vice president for research at Saint Luke’s Mid America Heart Institute, was the lead author of the STEP-HFpEF trial and presented the findings during the opening late breaking clinical trial session at the European Society of Cardiology Congress —the world’s largest cardiology conference— in Amsterdam, Netherlands. 

The results have been published in the New England Journal of Medicine at the time of the presentation. The findings have received the national and international coverage listed below. 

• CNN: Weight-loss drug Wegovy produces ‘largest benefit ever seen’ for patients with most common form of heart failure, trial finds

• US News & World Report: Wegovy May Be Valuable New Option for Heart Failure Patients

• CBS Evening News: Study Shows Wegovy May Reduce Risk of Heart Failure

• Good Morning America: New Study Highlights Benefits to Weight Loss Drugs

• The New York Times: New York Times: Obesity Treatment Relieves Heart Failure Symptoms, Drugmaker’s Study Finds

• The Wall Street Journal: Weight-Loss Drug Wegovy Also Works Against Heart Failure

• Healthline: Wegovy Reduced Heart Failure Symptoms, New Study Finds

• Nature: Semaglutide in Hfpef Across Obesity Class and By Body Weight Reduction: A Prespecified Analysis of the STEP-Hfpef Trial

• The Guardian: Weight-loss drug can reverse heart failure symptoms, study finds

• Healio: Semaglutide drives ‘substantial’ improvements in heart failure symptoms: STEP-HFpEF

• MedPage Today: Wegovy Reduces Heavy Symptom Burden of Obesity-Related Heart Failure

• WebMD: Weight Loss Drug Wegovy Also Works Against Heart Failure: Study

• Medscape: Wegovy Scores HFpEF Benefits in People With Obesity

• STAT News: Weight Loss Drug Wegovy Improves Function in People with Common Type of Heart Failure

• American College of Cardiology: Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-Related Heart Failure With Preserved Ejection Fraction - STEP-HFpEF

• tctMD: STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

• New York Post: Wegovy, Ozempic can help with heart failure symptoms, study finds

• The Times UK: Weight-loss injections like Ozempic could be key to curing heart failure

• Independent UK: Weight loss jabs improve heart failure symptoms in obese patients, says study

• American Journal of Managed Care: Results for Semaglutide Show Obesity Is a “Root Cause” of HFpEF; Payer Coverage Needed, Kosiborod Says

• HCPLive: Semaglutide 2.4 mg Shows Benefit as Treatment for Heart Failure with Obesity

• Patient Care: Semaglutide 2.4 mg Significantly Reduces HF Symptom Burden, Body Weight in Adults with HFpEF and Obesity

• PACE-CME: GLP-1RA improves HF symptoms and physical function in patients with HFpEF and obesity

• Cardiovascular Business: Weight loss drug semaglutide linked to multiple benefits for heart failure patients

• News Medical Life Science: Semaglutide could be a game-changer for patients with HFpEF and obesity

• MPR-Medical Professionals Reference: Semaglutide Beneficial for Patients With HFpEF and Obesity

• MedicineNet: Wegovy May Be Valuable New Option for Heart Failure Patients

• Fierce Pharma: On a roll, Novo's star obesity drug Wegovy shows benefits in patients with heart failure

• HealthManagement: #ESCCongress2023: Semaglutide Improves Heart Failure-Related Symptoms, Physical Function

• ScienceDirect: Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials